Travere Therapeutics to Present Abstracts on FILSPARI (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association - Seite 2

Poster: SUN-049
Poster Session: Clinical Glomerulonephritis 2
Exhibition Hall and Main Foyer; April 14, 2024, 5:45-6:45 p.m. ART

Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety
Poster: SUN-045
Poster Session: Clinical Glomerulonephritis 2
Exhibition Hall and Main Foyer; April 14, 2024, 5:45-6:45 p.m. ART

Preliminary Findings from the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients with Selected Proteinuric Glomerular Diseases
Poster: SUN-048
Poster Session: Clinical Glomerulonephritis 2
Exhibition Hall and Main Foyer; April 14, 2024, 5:45-6:45 p.m. ART

ANNA Poster Presentations

Sparsentan (SPAR), a Novel Non-immunosuppressive Therapy for Patients (pts) with Immunoglobulin A Nephropathy (IgAN): Pivotal Phase 3 PROTECT Trial Data
Exhibit Hall; April 15, 2024, 8:45-10:15 a.m. & 2:30-4 p.m.; April 16, 2024, 8:45-10:15 a.m. ET

Contextualizing the Humanistic Burdens of Focal Segmental Glomerular Sclerosis (FSGS) in HONUS Compared to External Controls in NHWS
Exhibit Hall; April 15, 2024, 8:45-10:15 a.m. & 2:30-4 p.m.; April 16, 2024, 8:45-10:15 a.m. ET

Indirect Comparisons of Humanistic Burdens Between Patients with Immunoglobulin A Nephropathy (IgAN) from HONUS and External Controls from NHWS
Exhibit Hall; April 15, 2024, 8:45-10:15 a.m. & 2:30-4 p.m.; April 16, 2024, 8:45-10:15 a.m. ET

Data in Kidney Failure (KF) Estimated by Treatment Effects on Proteinuria in Patients with Immunoglobulin A Nephropathy (IgAN)
Exhibit Hall; April 15, 2024, 8:45-10:15 a.m. & 2:30-4 p.m.; April 16, 2024, 8:45-10:15 a.m. ET

About IgA Nephropathy

IgA nephropathy (IgAN), also called Berger's disease, is a rare progressive kidney disease characterized by the buildup of immunoglobulin A (IgA), a protein that helps the body fight infections, in the kidneys. The deposits of IgA cause a breakdown of the normal filtering mechanisms in the kidney, leading to blood in the urine (hematuria), protein in the urine (proteinuria) and a progressive loss of kidney function. Other symptoms of IgAN may include swelling (edema) and high blood pressure.

IgAN is the most common type of primary glomerulonephritis worldwide and a leading cause of kidney failure due to glomerular disease. IgAN is estimated to affect up to 150,000 people in the U.S. and is one of the most common glomerular diseases in Europe and Japan.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com